At present, China’s biopharmaceuticals import and export are facing a good opportunity for development. With the strong support of the government and the efforts of the enterprises, China’s biopharmaceutical industry has made great progress, and its links with the international biopharmaceutical industry are getting closer. While maintaining a significant increase in imports of bio-pharmaceutical products, exports of some bio-pharmaceutical products have also been steadily increasing.
According to statistics collected by the China Chamber of Commerce for the Import and Export of Chinese Medicines and Health Products, China's import and export of biomedical products was 1.194 billion U.S. dollars in the first half of this year, an increase of 50.65% year-on-year. Among them, the export value was 100 million U.S. dollars, an increase of 26.89% year-on-year; the import value was 1.094 billion U.S. dollars, an increase of 53.26% year-on-year, and imports and exports both showed a trend of substantial growth. The development momentum was full. According to statistics from the Ministry of Industry and Information Technology, the number of biopharmaceutical companies in China has grown to 690 in 2011. The total output value of biopharmaceutical industry reached 159.214 billion yuan, operating income was 151.547 billion yuan, and total profit was 20.669 billion yuan, which accounted for 157.769 billion yuan in China's pharmaceutical industry output value, respectively. 10.14%, 9.94% of the main business income of the pharmaceutical industry was 1,525.467 billion yuan, and 13.11% of the total profit of the pharmaceutical industry was 157.689 billion yuan, but still lower than the proportion of the global biopharmaceutical industry in the pharmaceutical industry. This shows that China's biopharmaceutical industry also There is a lot of room for development. During the “Twelfth Five-Year Plan†period, China has listed biotechnology as one of the seven strategic emerging industries. The development of the biopharmaceutical industry has entered an important period of transition from imitation to imitation, and policy support has been increasing, such as the establishment of strategic emerging Special funds for industrial development, establishing a stable financial input growth mechanism, and supporting industrialization of innovation results. It can be predicted that the import and export of biomedical products in China will continue to maintain rapid growth in the second half of this year.
Exports: Asia becomes a major market Currently, most of the domestically listed biomedical products are biosimilars. According to reports, as of the end of 2011, China's 13 categories of 25 382 genetically engineered and genetically engineered vaccine products of different specifications were approved for listing, and only 6 of the 9 products with 21 specifications were original. Fortunately, more and more biopharmaceutical companies have taken advantage of their own engineering technology to move into the international market.
In the first half of this year, a total of 168 enterprises in China engaged in the export of biomedical products, and 23 enterprises exported more than 1 million US dollars. Aibo Biopharmaceutical (Hangzhou) Co., Ltd., Sichuan Yuanda Fuyang Pharmaceutical Co., Ltd., Shanghai Mérieux Bio-Engineering Co., Ltd, Yingke Innovation (Xiamen) Technology Co., Ltd., Shanghai YingBerken Medical Biotechnology Co., Ltd., Liaoning Chengda Biological Co., Ltd., Shanghai Laise Blood Products Co., Ltd., Chengdu Rongsheng Pharmaceutical Co., Ltd., Aikang Biotechnology (Hangzhou) Co., Ltd., and Lanzhou Bio-Technology Development Co., Ltd. ranked in the first half of this year's exports of biomedical products in China. The top 10, accounting for 62.12%. Among them, Aibo Bio-Pharmaceuticals (Hangzhou) Co., Ltd. accounted for as high as 34.11%. The company's colloidal gold labeling technology, monoclonal antibodies, polyclonal antibodies, gene recombinant antigens, synthetic antigens and other biological raw material technologies, and immunochromatography technology, etc. The research and development in the frontier biological field is at the leading domestic level.
In the first half of this year, China's biomedical products were exported to 141 countries and regions. The value of exports to Asia was US$35 million, an increase of 8.11% year-on-year. Asia was the major export market, accounting for 35.41% of the total. The top ten trade partners of China's biomedical product exports were the United States, Turkey, Germany, India, France, Egypt, Pakistan, the United Kingdom, Hong Kong, and Vietnam, which accounted for 64.8% of the total. Among them, the U.S. market accounted for 23.41% of the total market share. The two largest U.S. export companies, Aibo Biopharmaceuticals (Hangzhou) Co., Ltd. and Beijing Yiqiao Shenzhou Biotechnology Co., Ltd. accounted for 81.37% of the total. It is worth mentioning that all the recombinant proteins, antibodies, ELISA kits, and cDNA clones of Sinofee China are independently developed and produced. It takes only a few weeks from the gene sequence to the purification of monoclonal antibodies after 1-30 g purification. The fastest rate of antibody production in the world.
At present, European and American markets are very strict about the application for biosimilar drugs. At the same time, Chinese pharmaceutical companies lack a resounding brand overseas and adequate marketing networks. Under the current situation, China's biopharmaceutical companies can join forces with overseas companies to sell their biopharmaceutical products to overseas markets by leveraging the latter's advantages in drug registration, technology research and development, and marketing networks.
Since the beginning of the new century, as SARS, H5N1, H1N1 and other viruses have been raging around, various types of outbreaks have spread globally. The demand for the vaccine market has increased substantially. It is predicted that the global vaccine market sales will increase at a rate of 18% in 2011. The global vaccine market has sales of 30 billion U.S. dollars. China's vaccine is popular in Asia and Africa due to its high quality and low price, and it maintains a rapid growth momentum.
In the first half of this year, China’s human vaccine exports amounted to USD 7,910,800, accounting for 7.9% of China’s exports of biological and pharmaceutical products, and were exported to 25 countries and regions. The main export markets are India, Egypt, Bangladesh, Mongolia and the Philippines. The proportion of up to 66.98%, of which only India accounted for 24.48%. In the first half of the year, a total of 17 companies in China engaged in the export of vaccines for human use. Liaoning Chengda Biological Co., Ltd., Shanghai Dongbao Bio-Pharmaceutical Co., Ltd., Beijing Kexing Biological Products Co., Ltd. and Chengdu Institute of Biological Products are located in China's human vaccine exports. Ranked the top of the amount, accounting for 74.12%. Among them, Liaoning Chengda Biological Co., Ltd. has a high proportion of 37.06%. The company currently has more than 40 million doses of human rabies vaccine and more than 10 million doses of human inactivated vaccines for JE production. In particular, its use of rabies vaccines has broken the long-term monopoly of high-end human rabies vaccines used by multinational companies in China. The technical indicators have reached the advanced level of similar products of the world and have been exported to more than 10 countries such as India. The registration of products in many countries such as Vietnam, the serological results of the multi-point intradermal injection procedure of this product are obviously better than the similar products of multinational companies and will be popularized in Thailand soon. In addition, the company's inactivated JE vaccine does not contain antibiotics, preservatives, etc., and has strong international competitiveness. It has obtained Cambodia's registration approval and is registering products in India and other countries. After years of hard work, the Chengdu Institute of Biological Products has also successfully passed the review of the Indian drug regulatory agency. The JE vaccine with its own intellectual property rights has entered the Indian government procurement system.
The export value of commodities under the heading 3002909099, including human blood and other toxins including cultured microorganisms (excluding yeast and similar products), was US$4,717,800, an increase of 1.87% over the same period of last year, and was exported to 20 countries and regions. The export markets are Hong Kong, China, France, Vietnam, and India, accounting for 81.21% of the total, of which China's Hong Kong accounted for 46.1%. There are 11 companies in the country that manage the export of such commodities, among which Lanzhou Biotechnology Development Co., Ltd., Novozymes (Shenyang) Biological Processing Co., Ltd., Beijing Diltagin Biotech Co., Ltd., and Runying Bioengineering (Shanghai) Co., Ltd. Changchun Institute of Biological Products ranked among the top 5 exporters of such commodities in the first half of 2012, accounting for 99.35% of the total. Among them, Lanzhou Biotechnology Development Co., Ltd. has a share of 45.32%. The botulinum toxin type A independently developed by the company won the second prize of the National Science and Technology Progress Award and has obtained the registration certificate of the Korea Food and Drug Administration (KFDA). Already registered in more than 20 countries.
The export value of goods under the tariff line No. 3002100090 “Other antiserum, other blood and immune products†was US$78 million, accounting for 78.35% of the total exports of biological medicine products. It was exported to 140 countries and regions, and the main export market was The United States, Turkey, Germany, France and India accounted for 53.8% of the total. Among them, the United States accounted for 26.13%. There are 104 companies across the country that manage such exports. Aibo Bio-Pharmaceuticals (Hangzhou) Co., Ltd., Sichuan Yuanda Fuyang Pharmaceutical Co., Ltd., Shanghai Mérieux Bio-Engineering Co., Ltd, Yingke Innovation (Xiamen) Science and Technology Co., Ltd., and Shanghai BioBerken Medical Bio-Technology Co., Ltd. are located in this category. The top five commodities exports ranked at 63.57%. Among them, Aibo Bio-Pharmaceuticals (Hangzhou) Co., Ltd. and Sichuan Grand Sunyang Pharmaceutical Co., Ltd. accounted for 49.4% of the total. It is worth mentioning that Sichuan Grand Sunyang Pharmaceutical Co., Ltd. is the country's first batch of designated blood product companies specializing in the research, development, and manufacture of plasma protein drugs. In recent years, the company has increased its veins through technical innovations. Injection of human blood gamma globulin and other new product lines have become the largest blood products manufacturer in China that can handle plasma.
Imports: European and American companies monopolized the market From a global perspective, as early as 2010, biomedical products sales reached 140 billion US dollars, accounting for 16% of the global pharmaceutical market. By 2015, there will be 64 billion U.S. dollars worth of bio-patent drugs due, including many heavy products with annual sales exceeding 5 billion U.S. dollars. According to reports, by 2020, the proportion of biomedical products in global pharmaceutical sales will exceed one-third.
In the first half of this year, a total of 356 companies had imported bio-pharmaceutical products, and 77 companies had imported more than US$1 million. Shanghai Roche Pharmaceutical Co., Ltd., Roche Diagnostics (Shanghai) Co., Ltd., Abbott Trading (Shanghai) Co., Ltd. , China Animal Husbandry & Industry (Group) Corporation, Baxter Medical Products Trading (Shanghai) Co., Ltd., Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd., Shenzhen Sanofi Pasteur Biological Products Co., Ltd., and Yongyu (Shanghai) ) Pharmaceutical Logistics Operations Co., Ltd., Kerry Logistics (Shanghai Waigaoqiao) Co., Ltd. and Liaoning Huiming International Trade Co., Ltd. ranked among the top 10 biomedical product imports in China, accounting for 62.16%.
In the first half of this year, China has imported bio-pharmaceutical products from 42 countries and regions. Europe and North America are the major import markets. The proportion of the two markets is as high as 96.44%. The top ten trade partners of China's biopharmaceutical products are the United States, Germany, Switzerland, Austria, France, Ireland, Spain, Japan, the Netherlands, and the United Kingdom, accounting for 93.55%. Among them, the proportion of the United States, Germany and Switzerland alone is as high as 67.71%, and the market monopoly feature is very obvious.
In the first half of this year, China’s human vaccine imports amounted to US$62 million, an increase of 11.69% year-on-year. A total of six companies across the country operate imports of this type of goods. Shenzhen Sanofi Pasteur Biological Products Co., Ltd. topped the list of human vaccine imports, which accounted for 65.5% of the total. The company is mainly engaged in the import of bio-pharmaceutical product packaging, the main varieties. Includes Haemophilus influenzae type b conjugate vaccine, Group A meningococcal polysaccharide vaccine, Human rabies purified vaccine (Vero cells), Inactivated polio vaccine, Inactivated hepatitis A vaccine, Influenza virus split vaccine Wait.
The import value of goods under the tariff line No. 3002100090 “Other antiserum, other blood and immune products†was US$908 million, which accounted for 82.96% of the total. There were 269 companies in the country importing such commodities. Shanghai Roche Pharmaceutical Co., Ltd., Roche Diagnostic Products (Shanghai) Co., Ltd., Abbott Trading (Shanghai) Co., Ltd., Baxter Medical Products Trading (Shanghai) Co., Ltd., and Yongyu (Shanghai) Pharmaceutical Logistics Operations Co., Ltd. rank among such goods. The top 5 ranked, accounting for 52.65% of the total. Among them, Shanghai Roche Pharmaceutical Co., Ltd. and Roche Diagnostics (Shanghai) Co., Ltd. accounted for 35.71% of the total, and Roche's biopharmaceutical products include trastuzumab for injection (Herceptin) and bevac Bevacine injection (Avastin). Herceptin’s global sales reached US$4.17 billion in 2010, and its patents will expire in 2019; Avidin’s global sales in 2010 will reach US$5.54 billion and its patents will expire in 2019. Biopharmaceutical products imported by Abbott Trading (Shanghai) Co., Ltd. mainly include Adalimumab injection (Qiu Mei Le). Its 2010 global sales amounted to 5.98 billion U.S. dollars, and the patents will expire in 2018.
Eliminating bottlenecks and creating opportunities In recent years, although China's bio-pharmaceutical industry has made considerable progress, there are still significant gaps compared with developed countries in Europe and America, mainly in four aspects: First, serious shortage of biomedical R&D funding; Second, China's biopharmaceuticals The separation of production, education, research, and trade is severe. Third, R&D entities are research institutes and not enterprises. Biomedical research results are poorly targeted and the conversion rate is low. Fourth, there is a shortage of biomedical industrialization personnel in China. At present, the export of biomedical products in China is also mainly restricted by technical barriers such as foreign registration. The quality of biopharmaceuticals in foreign countries is very strict. In addition, the ability of companies to develop international markets is insufficient, and the funds and energy invested are not enough, resulting in a large deficit in the import and export trade of biopharmaceutical products in China.
To change this situation, it is necessary to increase investment in R&D, shorten the gap between key technologies and foreign companies, actively introduce technology and talents, and strengthen research on biomedical policies and regulations in developed countries and regions. In the future, the China Chamber of Commerce for the Import and Export of Medicines and Health Products will actively take the lead and coordinating role in four major areas and do a good job in related services: First, providing information services, including closely tracking the upgrading of international biopharmaceutical products, and doing a good job in investigations. Analyze and research, capture new products of large-scale biopharmaceutical companies at any time, especially the potential business opportunities of the products whose patents are about to expire, and help companies to carry out targeted development; second is to build a cooperation and exchange platform to capitalize on China’s biopharmaceutical research and development in June this year. The investment promotion delegation visited the United States to visit Yale University and Harvard University to reach an important consensus on the establishment of cooperation between production, education and research, and promote domestic enterprises to establish multi-level and different forms of cooperation with outstanding companies and cutting-edge scientific research institutions in the United States and other countries and regions. Improve communication between the two parties and develop personnel training. Third, provide professional services such as product registration and certification, make great efforts to help companies register through the World Health Organization, obtain UN purchase orders, and provide guidance for enterprises to open the international market; Fourth, coordinate domestic The relevant government department is Enterprises strive for more policies and financial support to help companies "go global" and "go up." We have reason to believe that, after hard work, local companies will certainly be able to open up the export space for China's biomedical products in the international market.
According to statistics collected by the China Chamber of Commerce for the Import and Export of Chinese Medicines and Health Products, China's import and export of biomedical products was 1.194 billion U.S. dollars in the first half of this year, an increase of 50.65% year-on-year. Among them, the export value was 100 million U.S. dollars, an increase of 26.89% year-on-year; the import value was 1.094 billion U.S. dollars, an increase of 53.26% year-on-year, and imports and exports both showed a trend of substantial growth. The development momentum was full. According to statistics from the Ministry of Industry and Information Technology, the number of biopharmaceutical companies in China has grown to 690 in 2011. The total output value of biopharmaceutical industry reached 159.214 billion yuan, operating income was 151.547 billion yuan, and total profit was 20.669 billion yuan, which accounted for 157.769 billion yuan in China's pharmaceutical industry output value, respectively. 10.14%, 9.94% of the main business income of the pharmaceutical industry was 1,525.467 billion yuan, and 13.11% of the total profit of the pharmaceutical industry was 157.689 billion yuan, but still lower than the proportion of the global biopharmaceutical industry in the pharmaceutical industry. This shows that China's biopharmaceutical industry also There is a lot of room for development. During the “Twelfth Five-Year Plan†period, China has listed biotechnology as one of the seven strategic emerging industries. The development of the biopharmaceutical industry has entered an important period of transition from imitation to imitation, and policy support has been increasing, such as the establishment of strategic emerging Special funds for industrial development, establishing a stable financial input growth mechanism, and supporting industrialization of innovation results. It can be predicted that the import and export of biomedical products in China will continue to maintain rapid growth in the second half of this year.
Exports: Asia becomes a major market Currently, most of the domestically listed biomedical products are biosimilars. According to reports, as of the end of 2011, China's 13 categories of 25 382 genetically engineered and genetically engineered vaccine products of different specifications were approved for listing, and only 6 of the 9 products with 21 specifications were original. Fortunately, more and more biopharmaceutical companies have taken advantage of their own engineering technology to move into the international market.
In the first half of this year, a total of 168 enterprises in China engaged in the export of biomedical products, and 23 enterprises exported more than 1 million US dollars. Aibo Biopharmaceutical (Hangzhou) Co., Ltd., Sichuan Yuanda Fuyang Pharmaceutical Co., Ltd., Shanghai Mérieux Bio-Engineering Co., Ltd, Yingke Innovation (Xiamen) Technology Co., Ltd., Shanghai YingBerken Medical Biotechnology Co., Ltd., Liaoning Chengda Biological Co., Ltd., Shanghai Laise Blood Products Co., Ltd., Chengdu Rongsheng Pharmaceutical Co., Ltd., Aikang Biotechnology (Hangzhou) Co., Ltd., and Lanzhou Bio-Technology Development Co., Ltd. ranked in the first half of this year's exports of biomedical products in China. The top 10, accounting for 62.12%. Among them, Aibo Bio-Pharmaceuticals (Hangzhou) Co., Ltd. accounted for as high as 34.11%. The company's colloidal gold labeling technology, monoclonal antibodies, polyclonal antibodies, gene recombinant antigens, synthetic antigens and other biological raw material technologies, and immunochromatography technology, etc. The research and development in the frontier biological field is at the leading domestic level.
In the first half of this year, China's biomedical products were exported to 141 countries and regions. The value of exports to Asia was US$35 million, an increase of 8.11% year-on-year. Asia was the major export market, accounting for 35.41% of the total. The top ten trade partners of China's biomedical product exports were the United States, Turkey, Germany, India, France, Egypt, Pakistan, the United Kingdom, Hong Kong, and Vietnam, which accounted for 64.8% of the total. Among them, the U.S. market accounted for 23.41% of the total market share. The two largest U.S. export companies, Aibo Biopharmaceuticals (Hangzhou) Co., Ltd. and Beijing Yiqiao Shenzhou Biotechnology Co., Ltd. accounted for 81.37% of the total. It is worth mentioning that all the recombinant proteins, antibodies, ELISA kits, and cDNA clones of Sinofee China are independently developed and produced. It takes only a few weeks from the gene sequence to the purification of monoclonal antibodies after 1-30 g purification. The fastest rate of antibody production in the world.
At present, European and American markets are very strict about the application for biosimilar drugs. At the same time, Chinese pharmaceutical companies lack a resounding brand overseas and adequate marketing networks. Under the current situation, China's biopharmaceutical companies can join forces with overseas companies to sell their biopharmaceutical products to overseas markets by leveraging the latter's advantages in drug registration, technology research and development, and marketing networks.
Since the beginning of the new century, as SARS, H5N1, H1N1 and other viruses have been raging around, various types of outbreaks have spread globally. The demand for the vaccine market has increased substantially. It is predicted that the global vaccine market sales will increase at a rate of 18% in 2011. The global vaccine market has sales of 30 billion U.S. dollars. China's vaccine is popular in Asia and Africa due to its high quality and low price, and it maintains a rapid growth momentum.
In the first half of this year, China’s human vaccine exports amounted to USD 7,910,800, accounting for 7.9% of China’s exports of biological and pharmaceutical products, and were exported to 25 countries and regions. The main export markets are India, Egypt, Bangladesh, Mongolia and the Philippines. The proportion of up to 66.98%, of which only India accounted for 24.48%. In the first half of the year, a total of 17 companies in China engaged in the export of vaccines for human use. Liaoning Chengda Biological Co., Ltd., Shanghai Dongbao Bio-Pharmaceutical Co., Ltd., Beijing Kexing Biological Products Co., Ltd. and Chengdu Institute of Biological Products are located in China's human vaccine exports. Ranked the top of the amount, accounting for 74.12%. Among them, Liaoning Chengda Biological Co., Ltd. has a high proportion of 37.06%. The company currently has more than 40 million doses of human rabies vaccine and more than 10 million doses of human inactivated vaccines for JE production. In particular, its use of rabies vaccines has broken the long-term monopoly of high-end human rabies vaccines used by multinational companies in China. The technical indicators have reached the advanced level of similar products of the world and have been exported to more than 10 countries such as India. The registration of products in many countries such as Vietnam, the serological results of the multi-point intradermal injection procedure of this product are obviously better than the similar products of multinational companies and will be popularized in Thailand soon. In addition, the company's inactivated JE vaccine does not contain antibiotics, preservatives, etc., and has strong international competitiveness. It has obtained Cambodia's registration approval and is registering products in India and other countries. After years of hard work, the Chengdu Institute of Biological Products has also successfully passed the review of the Indian drug regulatory agency. The JE vaccine with its own intellectual property rights has entered the Indian government procurement system.
The export value of commodities under the heading 3002909099, including human blood and other toxins including cultured microorganisms (excluding yeast and similar products), was US$4,717,800, an increase of 1.87% over the same period of last year, and was exported to 20 countries and regions. The export markets are Hong Kong, China, France, Vietnam, and India, accounting for 81.21% of the total, of which China's Hong Kong accounted for 46.1%. There are 11 companies in the country that manage the export of such commodities, among which Lanzhou Biotechnology Development Co., Ltd., Novozymes (Shenyang) Biological Processing Co., Ltd., Beijing Diltagin Biotech Co., Ltd., and Runying Bioengineering (Shanghai) Co., Ltd. Changchun Institute of Biological Products ranked among the top 5 exporters of such commodities in the first half of 2012, accounting for 99.35% of the total. Among them, Lanzhou Biotechnology Development Co., Ltd. has a share of 45.32%. The botulinum toxin type A independently developed by the company won the second prize of the National Science and Technology Progress Award and has obtained the registration certificate of the Korea Food and Drug Administration (KFDA). Already registered in more than 20 countries.
The export value of goods under the tariff line No. 3002100090 “Other antiserum, other blood and immune products†was US$78 million, accounting for 78.35% of the total exports of biological medicine products. It was exported to 140 countries and regions, and the main export market was The United States, Turkey, Germany, France and India accounted for 53.8% of the total. Among them, the United States accounted for 26.13%. There are 104 companies across the country that manage such exports. Aibo Bio-Pharmaceuticals (Hangzhou) Co., Ltd., Sichuan Yuanda Fuyang Pharmaceutical Co., Ltd., Shanghai Mérieux Bio-Engineering Co., Ltd, Yingke Innovation (Xiamen) Science and Technology Co., Ltd., and Shanghai BioBerken Medical Bio-Technology Co., Ltd. are located in this category. The top five commodities exports ranked at 63.57%. Among them, Aibo Bio-Pharmaceuticals (Hangzhou) Co., Ltd. and Sichuan Grand Sunyang Pharmaceutical Co., Ltd. accounted for 49.4% of the total. It is worth mentioning that Sichuan Grand Sunyang Pharmaceutical Co., Ltd. is the country's first batch of designated blood product companies specializing in the research, development, and manufacture of plasma protein drugs. In recent years, the company has increased its veins through technical innovations. Injection of human blood gamma globulin and other new product lines have become the largest blood products manufacturer in China that can handle plasma.
Imports: European and American companies monopolized the market From a global perspective, as early as 2010, biomedical products sales reached 140 billion US dollars, accounting for 16% of the global pharmaceutical market. By 2015, there will be 64 billion U.S. dollars worth of bio-patent drugs due, including many heavy products with annual sales exceeding 5 billion U.S. dollars. According to reports, by 2020, the proportion of biomedical products in global pharmaceutical sales will exceed one-third.
In the first half of this year, a total of 356 companies had imported bio-pharmaceutical products, and 77 companies had imported more than US$1 million. Shanghai Roche Pharmaceutical Co., Ltd., Roche Diagnostics (Shanghai) Co., Ltd., Abbott Trading (Shanghai) Co., Ltd. , China Animal Husbandry & Industry (Group) Corporation, Baxter Medical Products Trading (Shanghai) Co., Ltd., Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd., Shenzhen Sanofi Pasteur Biological Products Co., Ltd., and Yongyu (Shanghai) ) Pharmaceutical Logistics Operations Co., Ltd., Kerry Logistics (Shanghai Waigaoqiao) Co., Ltd. and Liaoning Huiming International Trade Co., Ltd. ranked among the top 10 biomedical product imports in China, accounting for 62.16%.
In the first half of this year, China has imported bio-pharmaceutical products from 42 countries and regions. Europe and North America are the major import markets. The proportion of the two markets is as high as 96.44%. The top ten trade partners of China's biopharmaceutical products are the United States, Germany, Switzerland, Austria, France, Ireland, Spain, Japan, the Netherlands, and the United Kingdom, accounting for 93.55%. Among them, the proportion of the United States, Germany and Switzerland alone is as high as 67.71%, and the market monopoly feature is very obvious.
In the first half of this year, China’s human vaccine imports amounted to US$62 million, an increase of 11.69% year-on-year. A total of six companies across the country operate imports of this type of goods. Shenzhen Sanofi Pasteur Biological Products Co., Ltd. topped the list of human vaccine imports, which accounted for 65.5% of the total. The company is mainly engaged in the import of bio-pharmaceutical product packaging, the main varieties. Includes Haemophilus influenzae type b conjugate vaccine, Group A meningococcal polysaccharide vaccine, Human rabies purified vaccine (Vero cells), Inactivated polio vaccine, Inactivated hepatitis A vaccine, Influenza virus split vaccine Wait.
The import value of goods under the tariff line No. 3002100090 “Other antiserum, other blood and immune products†was US$908 million, which accounted for 82.96% of the total. There were 269 companies in the country importing such commodities. Shanghai Roche Pharmaceutical Co., Ltd., Roche Diagnostic Products (Shanghai) Co., Ltd., Abbott Trading (Shanghai) Co., Ltd., Baxter Medical Products Trading (Shanghai) Co., Ltd., and Yongyu (Shanghai) Pharmaceutical Logistics Operations Co., Ltd. rank among such goods. The top 5 ranked, accounting for 52.65% of the total. Among them, Shanghai Roche Pharmaceutical Co., Ltd. and Roche Diagnostics (Shanghai) Co., Ltd. accounted for 35.71% of the total, and Roche's biopharmaceutical products include trastuzumab for injection (Herceptin) and bevac Bevacine injection (Avastin). Herceptin’s global sales reached US$4.17 billion in 2010, and its patents will expire in 2019; Avidin’s global sales in 2010 will reach US$5.54 billion and its patents will expire in 2019. Biopharmaceutical products imported by Abbott Trading (Shanghai) Co., Ltd. mainly include Adalimumab injection (Qiu Mei Le). Its 2010 global sales amounted to 5.98 billion U.S. dollars, and the patents will expire in 2018.
Eliminating bottlenecks and creating opportunities In recent years, although China's bio-pharmaceutical industry has made considerable progress, there are still significant gaps compared with developed countries in Europe and America, mainly in four aspects: First, serious shortage of biomedical R&D funding; Second, China's biopharmaceuticals The separation of production, education, research, and trade is severe. Third, R&D entities are research institutes and not enterprises. Biomedical research results are poorly targeted and the conversion rate is low. Fourth, there is a shortage of biomedical industrialization personnel in China. At present, the export of biomedical products in China is also mainly restricted by technical barriers such as foreign registration. The quality of biopharmaceuticals in foreign countries is very strict. In addition, the ability of companies to develop international markets is insufficient, and the funds and energy invested are not enough, resulting in a large deficit in the import and export trade of biopharmaceutical products in China.
To change this situation, it is necessary to increase investment in R&D, shorten the gap between key technologies and foreign companies, actively introduce technology and talents, and strengthen research on biomedical policies and regulations in developed countries and regions. In the future, the China Chamber of Commerce for the Import and Export of Medicines and Health Products will actively take the lead and coordinating role in four major areas and do a good job in related services: First, providing information services, including closely tracking the upgrading of international biopharmaceutical products, and doing a good job in investigations. Analyze and research, capture new products of large-scale biopharmaceutical companies at any time, especially the potential business opportunities of the products whose patents are about to expire, and help companies to carry out targeted development; second is to build a cooperation and exchange platform to capitalize on China’s biopharmaceutical research and development in June this year. The investment promotion delegation visited the United States to visit Yale University and Harvard University to reach an important consensus on the establishment of cooperation between production, education and research, and promote domestic enterprises to establish multi-level and different forms of cooperation with outstanding companies and cutting-edge scientific research institutions in the United States and other countries and regions. Improve communication between the two parties and develop personnel training. Third, provide professional services such as product registration and certification, make great efforts to help companies register through the World Health Organization, obtain UN purchase orders, and provide guidance for enterprises to open the international market; Fourth, coordinate domestic The relevant government department is Enterprises strive for more policies and financial support to help companies "go global" and "go up." We have reason to believe that, after hard work, local companies will certainly be able to open up the export space for China's biomedical products in the international market.
Warning Triangle,Safety Warning Triangle Kit,Roadside Warning Triangle,High Visibility Warning Triangle
Ningbo Zhihao Car Accessories Co.,Ltd. , https://www.zhihaoautoparts.com